Get the Stockscreener App
5.39
3.26%
0.17
After Hours:
5.52
0.13
+2.41%
Inmune Bio Inc stock is traded at $5.39, with a volume of 398.38K.
It is up +3.26% in the last 24 hours and down -18.58% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$5.22
Open:
$5.42
24h Volume:
398.38K
Relative Volume:
1.69
Market Cap:
$104.61M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-3.5461
EPS:
-1.52
Net Cash Flow:
$-11.98M
1W Performance:
+4.46%
1M Performance:
-18.58%
6M Performance:
-54.13%
1Y Performance:
-20.38%
1-Day Range:
$5.23
$5.42
1-Week Range:
$4.81
$5.745
52-Week Range:
$4.81
$14.74
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Analytical Overview: INmune Bio Inc (INMB)’s Ratios Tell a Financial Story - The Dwinnex
INmune Bio Inc [INMB] Investment Guide: What You Need to Know - Knox Daily
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease - The Manila Times
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease - Post Register
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease - StockTitan
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal (NASDAQ:INMB) - Seeking Alpha
CVI Holdings LLC Purchases New Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
CVI Holdings LLC Purchases New Position in INmune Bio, Inc. (NASDAQ:INMB) - MarketBeat
Raymond James Initiates Coverage of INmune Bio (INMB) with Outperform Recommendation - MSN
Achieve, INmune, Lenz stocks win bullish view from RayJay - Seeking Alpha
INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Raymond James - Defense World
INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Raymond James - MarketBeat
INmune Bio reports progress in prostate cancer trial By Investing.com - Investing.com Canada
INmune Bio reports progress in prostate cancer trial - Investing.com
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort - The Manila Times
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort - EIN News
UCB rapidly bolsters blockbuster potential for Bimzelx with 3 new FDA approvals - FiercePharma
What is the investor’s view on Immunic Inc (IMUX)? - US Post News
You might want to take a look at Inuvo Inc (INUV) now - SETE News
Imunon Inc (IMNN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Gaining Ground: Universe Pharmaceuticals INC (UPC) Closes Lower at 0.29, Down -13.83 - The Dwinnex
Innate Pharma Advances Novel Cancer Treatment - TipRanks
Century Therapeutics, Inc. (NASDAQ:IPSC) Stake Cut by Federated Hermes Inc. - MarketBeat
Innate Pharma: green light from the FDA for a study - Marketscreener.com
Itau Unibanco Holding S.A. Trims Stock Holdings in Micron Technology, Inc. (NASDAQ:MU) - Defense World
Integrated BioPharma (OTCMKTS:INBP) Posts Quarterly Earnings Results - Defense World
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt (NASDAQ:IBRX) - Seeking Alpha
Mutual of America Capital Management LLC Sells 5,171 Shares of CubeSmart (NYSE:CUBE) - Defense World
INmune Bio stock hits 52-week low at $5.17 amid market challenges By Investing.com - Investing.com South Africa
INmune Bio stock hits 52-week low at $5.17 amid market challenges - Investing.com
How To Trade (INMB) - Stock Traders Daily
Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA - Proactive Investors Australia
You might want to take a look at Imunon Inc (IMNN) now - SETE News
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com Australia
Raymond Tesi Buys Handful Of Shares In INmune Bio - Simply Wall St
BTIG maintains Buy rating on INmune Bio shares with steady price target - Investing.com Canada
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World
BTIG maintains Buy rating on INmune Bio shares with steady price target - Investing.com
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com
Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News
Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex
INmune Bio reports strong data from Alzheimer's trial - Investing.com
INmune Bio reports strong data from Alzheimer's trial By Investing.com - Investing.com Canada
INmune Bio reports strong data from Alzheimer's trial - Investing.com India
INmune Bio reports strong data from Alzheimer's trial By Investing.com - Investing.com South Africa
INmune Bio announces results of additional interim analysis of Phase 2 trial - TipRanks
INmune Bio reports strong data from Alzheimer's trial By Investing.com - Investing.com UK
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints - StockTitan
How to interpret INmune Bio Inc (INMB)’s stock chart patterns - US Post News
INmune Bio, Inc. (NASDAQ:INMB) CEO Raymond Joseph Tesi Purchases 15,380 Shares - Defense World
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):